O-30 - A LOCAL OUTBREAK OF IATROGENIC BOTULISM ASSOCIATED WITH COSMETIC INJECTIONS OF BOTULINUM NEUROTOXIN-CONTAINING PRODUCTS, ENGLAND, 2025
Journal of Public Health · 09.07.2026 · 48 (Supplement_1) · i14-i14
DOI: 10.1093/pubmed/fdag046.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Public Health, online erschienen am 09.07.2026. Verfasst von Mr Joe Jasperse und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Iatrogenic botulism is a rare but serious illness caused by the systemic spread of an excessive or improperly administered dose of botulinum neurotoxin (BoNT) during medical or cosmetic procedures. Here we report the investigation of an outbreak of iatrogenic botulism linked to cosmetic injections in North East England.
Objectives
To identify risk factors for illness and inform recommendations for minimising future public health risk.
Methods
We defined a case as an individual with a clinical diagnosis of botulism who received a cosmetic injection with a BoNT-containing product from a practitioner in North East England since 1 May 2025 and developed at least one compatible symptom (difficulty swallowing, difficulty breathing, altered speech) within four weeks. We conducted a case-control study with controls recruited via social media and used univariable Firth logistic regression to analyse potential risk factors. An endopeptidase immunoassay was used to estimate the potency of a vial of unlicensed product seized from a local supplier.
Results
Overall, 25 cases were identified with onset dates ranging from 18 May to 9 June 2025. Most cases were female (88%) and the median age was 43 years (range: 25-82 years). Cases were significantly more likely to have attended two specific local practitioners (both p<0.001), reported receiving an unlicensed product (p < 0.001) and received more injections than at their previous appointment (p = 0.029). The estimated potency of the seized unlicensed product (370 units/vial, 95% CI: 327–419 units) was 85% higher than that listed on its labelling (200 units/vial).
Conclusions
Stronger regulation of cosmetic practitioners should be introduced in the UK, where no mandatory training or licensing requirements are currently in place despite rising demand for cosmetic procedures. Raising public awareness around the importance of using licensed products, as well as disrupting the supply of unlicensed products, will help further reduce public health risk.
Zitieren
APA
Jasperse, M. J., Wilson, K., Akbar, S., Hayden, I., Naseem, Q., Coglan, A., Hewson, M., Young, A., Fang, M., Liu, Y., Darke, J., Wong, V., Godbole, G., & Hughes, G. J. (2026). O-30 - A LOCAL OUTBREAK OF IATROGENIC BOTULISM ASSOCIATED WITH COSMETIC INJECTIONS OF BOTULINUM NEUROTOXIN-CONTAINING PRODUCTS, ENGLAND, 2025. Journal of Public Health, 48(Supplement_1), i14-i14. https://doi.org/10.1093/pubmed/fdag046.026
Vancouver
Jasperse MJ, Wilson K, Akbar S, Hayden I, Naseem Q, Coglan A, et al. O-30 - A LOCAL OUTBREAK OF IATROGENIC BOTULISM ASSOCIATED WITH COSMETIC INJECTIONS OF BOTULINUM NEUROTOXIN-CONTAINING PRODUCTS, ENGLAND, 2025. Journal of Public Health. 2026;48(Supplement_1):i14-i14. doi:10.1093/pubmed/fdag046.026
BibTeX
@article{Jasperse2026,
author = {Jasperse, Mr Joe and Wilson, Kate and Akbar, Sana and Hayden, Iain and Naseem, Qudsia and Coglan, Amii and Hewson, Matt and Young, Alan and Fang, Min and Liu, Yvonne and Darke, Joanne and Wong, Vanessa and Godbole, Gauri and Hughes, Gareth J},
title = {O-30 - A LOCAL OUTBREAK OF IATROGENIC BOTULISM ASSOCIATED WITH COSMETIC INJECTIONS OF BOTULINUM NEUROTOXIN-CONTAINING PRODUCTS, ENGLAND, 2025},
journal = {Journal of Public Health},
year = {2026},
volume = {48},
number = {Supplement_1},
pages = {i14--i14},
doi = {10.1093/pubmed/fdag046.026}
}
EUVIMED